(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday in its ...

It's the moment of truth for AbbVie. The first Humira biosimilar is set to launch later this month, with many more to follow throughout the year. AbbVie maintains that it is well prepared. After a ...

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...

While flashy growth stocks often steal the spotlight, some of the market’s most consistent winners are hiding in plain sight.

AbbVie owns two of the best-selling drugs in the world in Humira and Imbruvica. But to build and defend its market monopoly for the two heavyweights, the company has repeatedly raised prices and ...

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Evernorth's Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs, the company announced Thursday. Accredo is the specialty pharmacy segment within Evernorth ...

This week CVS Health launched Cordavis, a wholly owned subsidiary that will work with manufacturers to commercialize and/or co-produce biosimilar products for the U.S. pharmaceutical market. The ...